Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
-- NUZYRA® (omadacycline) Net Sales increased 26% to $1.7 Million in the Second Quarter of 2019 -- -- Over 50% of Commercial Lives in U.S. now have Access to NUZYRA -- -- Paratek Promotes Evan Loh, M.D. to Chief Executive Officer …